Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on

Published:2019-12-10 Issue:2 Volume:38 Page:129-136
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Molica Stefano¹^ORCID,Matutes Estella²,Tam Constantine³,Polliack Aaron⁴

Affiliation:

1. Department of Hematology‐Oncology Azienda Ospedaliera Pugliese‐Ciaccio Catanzaro Italy

2. Haematopathology Unit, Hospital Clinic Barcelona University Barcelona Spain

3. St Vincent's Hospital Peter MacCallum Cancer Centre and University of Melbourne Melbourne Victoria Australia

4. Department of Hematology Hadassah‐Hebrew‐University Medical Center Jerusalem Israel

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2695

Reference68 articles.

1. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

2. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

3. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

4. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

5. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multifunctional Ag-decorated core-shell heterojunction of red phosphorus/silicon carbide nanowires for highly sensitive SERS-based monitoring of ibrutinib;Surfaces and Interfaces;2024-03

2. Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials;Expert Review of Anticancer Therapy;2023-11-28

3. Redefining efficacy and safety endpoints for chronic lymphocytic leukemia in the era of targeted therapy;Expert Review of Hematology;2023-10-16

4. Identification and characterization of stress degradation products of ibrutinib by LC-UV/PDA and LC-Q/TOF-MS studies;European Journal of Mass Spectrometry;2023-08

5. Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option;Cancers;2023-07-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3